🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Biomarker-guided decision making in clinical drug development for neurodegenerative disorders tinyurl.com/42peuas7 This review discusses the implementation of a growing array of biomarkers across neurodegenerative disorders to expedite and de-risk drug development #ADPD2025

Analysis of China-to-West pharmaceutical licensing deals in 2024 nature.com/articles/d41... This article analyses China-to-West pharma deals in 2024 by examining 48 deals by asset stage, treatment modality and disease areas.

FDA new drug approvals in Q1 2025 tinyurl.com/5n8ak54h Only 7 new drugs were approved by the FDA in Q1, but 2 are potential blockbusters - the sodium channel inhibitor suzetigrine for pain and the TROP2-targeted antibody-drug conjugate datopotamab deruxtecan for breast cancer

For readers interested in the development of sodium channel inhibitors for the treatment of pain, as well as other indications such as epilepsy, here's a recent review nature.com/articles/s4157…

For readers interested in drug development for neurodegenerative diseases, this review in the April issue discusses mitophagy enhancement with compounds such as USP30 inhibitors and PINK1 activators as a therapeutic strategy tinyurl.com/bddchuez rdcu.be/ehQWc

Back to the drawing board for anhedonia drugs nature.com/articles/d4157… Johnson & Johnson has discontinued development of aticaprant for depression with anhedonia, a blow to hopes for drugs for ‘domains’ of psychiatric disorders

For readers interested in drug development for psychiatric disorders, this article discusses reasons for clinical trial failures and strategies to improve the translational predictivity of preclinical models nature.com/articles/s4157… rdcu.be/eh0Xn

The aryl hydrocarbon receptor: a rehabilitated target for therapeutic immune modulation nature.com/articles/s4157… This new review discusses how the AHR - once avoided in drug development - is now being targeted for inflammatory disorders, cancer and infectious diseases

$XBI Courtesy Nature Reviews Drug Discovery $TAK Head of R&D, Andy Plump, on biotech investment in current climate — Filtered out a lot of the background noise, and what’s competitive deserves to be competitive. We’re still paying a lot for it, but it’s the market price.

Back to therapeutic modality basics nature.com/articles/d4157… Andy Plump, head of R&D Takeda, discusses the company’s evolving pipeline, therapeutic modalities, and upheaval in biotech, the NIH and the FDA in our latest interview

The impact of accelerated drug marketing registration procedures on the review and approval of new drugs in China nature.com/articles/d4157… This new article analyses the effectiveness of China’s regulatory pathways in speeding the approval of important new drugs

The expanding universe of GLP-1 medicines-with dozens of new molecular entities in the clinic, how will they differentiate beyond #weightloss #obesity #diabetes #heartdiseasen Nature Reviews Drug Discovery nature.com/articles/s4157…

GLP-1-based therapies for diabetes, obesity and beyond tinyurl.com/ph3fn4eh This new review by Daniel J Drucker profiles GLP-1-based medicines, discussing optimization of pharmacokinetics and tolerability, engagement of new therapeutically useful pathways and safety aspects

For readers interested in targeting GPCRs such as GLP-1R, this review in the April issue discusses how functional dynamics studies are revealing new routes to identify drug candidates with tailored selectivity and efficacy profiles tinyurl.com/muj99nt6 rdcu.be/ejRO8

$MDGL Rezdiffra Q1 sales $137.3M vs consensus $112.5M per Visible Alpha.

For readers interested in drugs for metabolic dysfunction-associated steatohepatitis (MASH), such as the first-in-class therapy resmetirom (Rezdiffra; Madrigal Pharmaceuticals), here's a recent review nature.com/articles/s4157… rdcu.be/ekg9V

Application of new approach methodologies for nonclinical safety assessment of drug candidates tinyurl.com/3t9cuxdy This new article discusses the promise of NAMs to better predict safety risks, especially for drugs for which animal models alone have limited applicability

Our May issue is live! Read about sodium channels as therapeutic targets, strategies to manage CAR-T cell toxicity, fibroblast growth factor-based drug discovery, challenges for anhedonia drug development and more here nature.com/nrd/volumes/24…

A 'one-drug-fits-all' approach to mental health often doesn’t work, but hopes for drugs for ‘domains’ of psychiatric disorders took a blow with the discontinuation of J&J's aticaprant for depression with anhedonia. Read about paths forward in the May issue tinyurl.com/2ujb25vu

FDA approves J&J’s FcRN blocker for generalized myasthenia gravis nature.com/articles/d4157… The antibody is entering an increasingly crowded gMG market, but J&J expects that it could surpass $5 billion per year in sales as it is rolled out for other autoantibody-driven diseases